Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2012

Liao Wei-Yu, Shih Jin-Yuan, Chang Gee-Chen, Cheng Yu-Kai, Yang James Chih-Hsin, Chen Yuh-Min, Yu Chong-Jen

Abstract excerpt

INTRODUCTION: Elevated DNA-repair capacity has been related to chemoresistance of platinum doublet chemotherapy in non-small-cell lung cancer (NSCLC). We evaluated whether single nucleotide polymorphisms of DN- repair genes excision repair cross-complementing group 1 (ERCC1), ERCC2, x-ray repair cross-complementing group 1 (XRCC1), XRCC3, and RRM1 associate with treatment outcome in NSCLC patients receiving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Gemcitabine

Share to Platinum

Share to Ribonucleotide Reductases

Share to Taiwan

Share to X-ray Repair Cross Complementing Protein 1

Source

Identifiers

PMID: 22551904
DOI: 10.1097/JTO.0b013e31824fe98c

Genes

XRCC1
ERCC2
ERCC1
RRM1
XRCC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.PMID 22551904Read ↗

Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.Semantic proximity Read ↗

Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.Semantic proximity Read ↗

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.Semantic proximity Read ↗

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapySemantic proximity Read ↗

DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy.Semantic proximity Read ↗

Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.Semantic proximity Read ↗

DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinomaSemantic proximity Read ↗

Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.Semantic proximity Read ↗

[Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].Semantic proximity Read ↗

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.Semantic proximity Read ↗

Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.